Long-Acting Cabotegravir Protects Macaques Against Repeated Penile Simian-Human Immunodeficiency Virus Exposures. (4th March 2020)

• Record Type: Journal Article
• Authors: Dobard, Charles; Makarova, Natalia; Nishiura, Kenji; Dinh, Chuong; Holder, Angela; Sterling, Mara; Lipscomb, Jonathan; Mitchell, James; Deyounks, Frank; Garber, David; Khalil, George; Spreen, William; Heneine, Walid; García-Lerma, J Gerardo
• Is Part Of: Journal of infectious diseases. Volume 222:Number 3(2020)
• Page Start: 391
• Page End: 395
• Publication Date: 2020-03-04
• Subjects: long-acting HIV PrEP -- penile transmission macaque model -- penile pharmacokinetics -- repeat-challenge; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiaa095
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: We used a novel penile simian-human immunodeficiency virus (SHIV) transmission model to investigate whether long-acting cabotegravir (CAB LA) prevents penile SHIV acquisition in macaques. Twenty-two macaques were exposed to SHIV via the foreskin and urethra once weekly for 12 weeks. Of these, 6 received human-equivalent doses of CAB LA, 6 received oral emtricitabine/tenofovir disoproxil fumarate, and 10 were untreated. The efficacy of CAB LA was high (94.4%; 95% confidence interval, 58.2%–99.3%) and similar to that seen with oral emtricitabine/tenofovir disoproxil fumarate (94.0%; 55.1%–99.2%). The high efficacy of CAB LA in the penile transmission model supports extending the clinical advancement of CAB LA preexposure prophylaxis to heterosexual men. Abstract : We used a macaque model of penile simian-human immunodeficiency virus transmission to investigate the efficacy of long-acting cabotegravir (CAB LA) preexposure prophylaxis against penile infection. CAB LA showed high protection, supporting its clinical development for preexposure prophylaxis in heterosexual men.